NCT01007851

Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: V.K.V. American Hospital, Istanbul · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	triptorelin acetate	single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
DRUG	NaCl %0.9	0.1 ml sterile saline sc injection 3 days after embryo transfer

Timeline

• Start date: 2006-09-01
• Completion: 2007-12-01
• First posted: 2009-11-04
• Last updated: 2009-11-04

Locations

1 site across 1 country: Turkey (Türkiye)